Compugen

Company Overview

Snapshot

Founded in February 1993, Compugen operates with 51–200 employees and has raised a total of $141.92 million across 7 funding rounds from 3 investors. The company went public on NASDAQ in August 2000 and on TASE in January 2002.

Business overview

Compugen is a clinical-stage drug-discovery and development company focused on immuno-oncology. The company leverages a predictive-discovery infrastructure to advance a therapeutic pipeline aimed at harnessing the immune system to eradicate cancer. Its pipeline is based on novel, Compugen-discovered immune checkpoint candidates designed to address unmet medical needs in various cancer types and patient populations, both as monotherapies and in combination. Compugen specializes in oncology and immunology, with an expanding focus on myeloid target candidates within the tumor microenvironment, operating within the Health Tech & Life Sciences sector.

Strategic signal

Compugen is actively engaged in presenting its research and clinical data at prominent scientific conferences, indicating ongoing progress and validation of its drug discovery efforts. In October 2025, the company is scheduled to present at SITC, and in September 2025, it will present research at the Single Cell Genomics Conference. These consistent presentations highlight Compugen's commitment to sharing scientific advancements and maintaining visibility within the immuno-oncology community, signaling continued development and potential future breakthroughs to investors.

Company Intelligence Q&A

When did Compugen go public on NASDAQ?

Compugen went public on NASDAQ in August 2000.

When did Compugen go public on TASE?

Compugen went public on TASE in January 2002.

What was a significant clinical development for Compugen in September 2020?

In September 2020, Compugen dosed the first patient in a Phase 1/2 triple combination study of COM701 with Bristol Myers Squibb's Opdivo® and an anti-TIGIT antibody.

What intellectual property expansion did Compugen achieve in October 2023?

In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any anti-PVRIG, TIGIT, and PD-1 antibody for the treatment of cancer.

What new data did Compugen present at SITC in November 2023?

In November 2023, Compugen presented new data at SITC suggesting the leading edge of its anti-IL18 Binding Protein Antibody, COM503, in treating cancer.